Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,006 public trials 571 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

NCT03944057

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Beijing Chao-Yang Hospital, Capital Medical University Beijing, Beijing Municipality, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Guangdong Provincial Peoples Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital Guangzhou, Guangdong, China
View all 17 locations
View Trial Details
Completed

A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat

NCT04150289

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • American Health Network Indiana Indianapolis, Indiana, United States
  • Southern Nevada Cancer Research Foundation and Optum Cancer Care Las Vegas, Nevada, United States
  • Oncology Specialists of Charlotte Charlotte, North Carolina, United States
  • Southern Oncology Specialists Huntersville, North Carolina, United States
View Trial Details
Completed

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma

NCT04136756

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +21 more
Locations
  • Western Regional Medical Center - CTCA Goodyear, Arizona, United States
  • City of Hope Duarte, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
View all 13 locations
View Trial Details
Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00002878

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of California San Diego Cancer Center La Jolla, California, United States
  • UCSF Cancer Center and Cancer Research Institute San Francisco, California, United States
  • CCOP - Christiana Care Health Services Wilmington, Delaware, United States
  • Walter Reed Army Medical Center Washington D.C., District of Columbia, United States
View all 40 locations
View Trial Details
Completed

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • St Francis Hospital and Medical Center Hartford, Connecticut, United States
  • University of Chicago Chicago, Illinois, United States
  • Eastern Maine Medical Center Brewer, Maine, United States
View Trial Details
Completed

Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

NCT03001804

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Landeskrankenhaus Kirchdorf Kirchdorf, Austria
  • Klinikum Klagenfurt am Wörthersee Klagenfurt, Austria
  • Kepleruniversitätsklinikum GmbH, Hämatologie und Internistische Onkologie Linz, Austria
  • Ordensklinikum Linz GmbH Elisabethinen Linz, Austria
View Trial Details
Completed

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT04754100

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida Louisville, Kentucky, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Cincinnati Cancer Center Cincinnati, Ohio, United States
View Trial Details

Related conditions